Retatrutide
Metabolic
A triple GIP/GLP-1/glucagon receptor agonist representing the next generation of metabolic peptides. Phase 2 trials showed up to 24% body weight reduction.
MetabolicFat LossAppetite ControlBlood Sugar ControlNauseaDiarrheaWeight LossSubcutaneous (SubQ)
Community
1
Tracking
9
Doses Logged
1mg/week
Common Dose
—
Adverse Rate
All dosages:1mg/week4mg/week8mg/week12mg/week
Reported Adverse Effects
No adverse effects reported yet
Community Consensus
No consensus claims yet — be the first to contribute
Literature
No studies linked yet — know of one? Share it in the discussion
Discussion
No discussion yet — be the first to share your experience